<bill session="117" type="s" number="6" updated="2023-08-15T19:45:20Z">
  <state datetime="2022-11-17">REFERRED</state>
  <status>
    <introduced datetime="2022-11-17"/>
  </status>
  <introduced datetime="2022-11-17"/>
  <titles>
    <title type="display">Biosimilar Red Tape Elimination Act</title>
    <title type="short" as="introduced">Biosimilar Red Tape Elimination Act</title>
    <title type="official" as="introduced">A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.</title>
  </titles>
  <sponsor bioguide_id="L000577"/>
  <cosponsors/>
  <actions>
    <action datetime="2022-11-17">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-11-17" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-08-15T19:31:06Z" status="Introduced in Senate">Biosimilar Red Tape Elimination Act

This bill removes and otherwise modifies certain requirements related to the approval of biosimilars, such as prohibiting the Food and Drug Administration from requiring studies that assess the risks of switching between the biosimilar and the reference biologic.</summary>
</bill>
